Equities Analysts Issue Forecasts for Biogen FY2025 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 EPS estimates for Biogen in a research note issued to investors on Thursday, July 10th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $14.65 per share for the year, down from their prior forecast of $14.90. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen's FY2028 earnings at $16.80 EPS and FY2029 earnings at $18.95 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The company had revenue of $2.43 billion during the quarter, compared to analysts' expectations of $2.25 billion. Biogen had a net margin of 15.07% and a return on equity of 14.03%. Biogen's revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $3.67 earnings per share.

BIIB has been the subject of a number of other research reports. Oppenheimer set a $205.00 price objective on shares of Biogen in a report on Friday, May 2nd. Truist Financial dropped their price objective on shares of Biogen from $210.00 to $199.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Argus cut shares of Biogen from a "buy" rating to a "hold" rating in a report on Friday, April 4th. Hsbc Global Res cut shares of Biogen from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Finally, Royal Bank Of Canada set a $213.00 price objective on shares of Biogen and gave the company an "outperform" rating in a report on Wednesday, June 25th. Twenty equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $188.48.

Biogen Price Performance

Biogen stock opened at $134.21 on Monday. The company's 50 day simple moving average is $128.17 and its 200-day simple moving average is $133.85. The company has a market capitalization of $19.67 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 1.07 and a beta of 0.14. Biogen has a 1 year low of $110.04 and a 1 year high of $236.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.01 and a current ratio of 1.44.

Hedge Funds Weigh In On Biogen

A number of large investors have recently bought and sold shares of the company. Signaturefd LLC raised its position in Biogen by 3.5% during the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock worth $320,000 after buying an additional 71 shares during the last quarter. Wedmont Private Capital increased its holdings in shares of Biogen by 3.8% in the 2nd quarter. Wedmont Private Capital now owns 2,190 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 81 shares in the last quarter. Israel Discount Bank of New York increased its holdings in shares of Biogen by 6.2% in the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 82 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in shares of Biogen by 4.1% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 2,343 shares of the biotechnology company's stock valued at $358,000 after purchasing an additional 92 shares in the last quarter. Finally, Quent Capital LLC increased its holdings in shares of Biogen by 31.2% in the 1st quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.